Inhibikase Therapeutics (IKT) News Today $1.80 -0.04 (-2.17%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Stonepine Capital Management LLC Sells 217,415 Shares of Inhibikase Therapeutics, Inc. $IKTAugust 26 at 7:38 AM | marketbeat.comInhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy OfficerAugust 19, 2025 | globenewswire.comInhibikase Therapeutics Reports Q2 2025 Financials and ProgressAugust 15, 2025 | msn.comInhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent ActivityAugust 14, 2025 | globenewswire.comInhibikase Therapeutics (NYSE:IKT) Shares Down 6.6% - Should You Sell?July 25, 2025 | marketbeat.comIKT Inhibikase Therapeutics, Inc. - Seeking AlphaJuly 3, 2025 | seekingalpha.comInhibikase Therapeutics (NYSE:IKT) Trading Down 5.1% - What's Next?July 3, 2025 | marketbeat.comInhibikase Therapeutics shareholders elect directors and approve equity plan changesJuly 2, 2025 | investing.comInhibikase Therapeutics Insiders Placed Bullish Bets Worth US$2.70mJune 30, 2025 | finance.yahoo.comMillennium Management LLC Invests $462,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT)June 10, 2025 | marketbeat.comInhibikase Therapeutics Reports Q1 2025 Financial ResultsMay 22, 2025 | tipranks.comSoleus Capital Management L.P. Takes $20.56 Million Position in Inhibikase Therapeutics, Inc. (NYSE:IKT)May 21, 2025 | marketbeat.comStonepine Capital Management LLC Makes New $3.68 Million Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)May 20, 2025 | marketbeat.comInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent ActivityMay 14, 2025 | finance.yahoo.comInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent ActivityMay 14, 2025 | globenewswire.comFairmount Funds Management LLC Purchases Shares of 6,125,000 Inhibikase Therapeutics, Inc. (NYSE:IKT)May 10, 2025 | marketbeat.comBlackstone Inc. Makes New Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)May 8, 2025 | marketbeat.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)May 5, 2025 | prnewswire.comGeode Capital Management LLC Purchases 272,813 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT)May 3, 2025 | marketbeat.comInhibikase Therapeutics: A Hold With Uncertain Prospects In PAHMay 2, 2025 | seekingalpha.comNantahala Capital Management LLC Makes New $7.12 Million Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)April 30, 2025 | marketbeat.comInhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-marketApril 16, 2025 | nasdaq.comInhibikase Therapeutics Advances PAH Treatment with New LeadershipApril 14, 2025 | tipranks.comInhibikase Therapeutics announces appointment of McIntyre as CFOApril 14, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial OfficerApril 14, 2025 | globenewswire.comADAR1 Capital Management LLC Takes $16.59 Million Position in Inhibikase Therapeutics, Inc. (NYSE:IKT)April 9, 2025 | marketbeat.comHedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term lossesApril 4, 2025 | finance.yahoo.comInhibikase Therapeutics (NYSE:IKT) Earns "Neutral" Rating from HC WainwrightMarch 29, 2025 | marketbeat.comInhibikase Therapeutics (IKT) Receives a Hold from H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent ActivityMarch 27, 2025 | globenewswire.comInhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.9% - What's Next?March 18, 2025 | marketbeat.comInhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSOFebruary 24, 2025 | markets.businessinsider.comInhibikase Announces Expansion of Senior Leadership TeamFebruary 24, 2025 | globenewswire.comInhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthFebruary 18, 2025 | finanznachrichten.deInhibikase Therapeutics appoints Mark Iwicki as CEOFebruary 18, 2025 | markets.businessinsider.comInhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s GrowthFebruary 18, 2025 | finance.yahoo.comInhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthFebruary 18, 2025 | globenewswire.comWhat is HC Wainwright's Estimate for IKT Q1 Earnings?February 17, 2025 | marketbeat.comHC Wainwright & Co. Downgrades Inhibikase Therapeutics (IKT)February 13, 2025 | msn.comInhibikase Therapeutics downgraded to Neutral from Buy at H.C. WainwrightFebruary 12, 2025 | markets.businessinsider.comInhibikase Therapeutics (NYSE:IKT) Downgraded to Neutral Rating by HC WainwrightFebruary 12, 2025 | marketbeat.comInhibikase Halts Parkinson's Drug Development to Focus on PAHJanuary 30, 2025 | msn.comInhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in studyJanuary 29, 2025 | reuters.comInhibikase Therapeutics (NYSE:IKT) Shares Down 2.5% - Should You Sell?January 28, 2025 | marketbeat.comBullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of StockJanuary 21, 2025 | finance.yahoo.comInhibikase Therapeutics (NYSE:IKT) Trading 3.4% Higher - Still a Buy?December 27, 2024 | marketbeat.comInhibikase Therapeutics (NYSE:IKT) Stock Price Up 7% - What's Next?November 30, 2024 | marketbeat.comInhibikase Therapeutics files to sell 58.31M shares of common stock for holdersNovember 19, 2024 | markets.businessinsider.comInhibikase: Potential To Improve Current Treatment Options For PAH PatientsNovember 19, 2024 | seekingalpha.comInhibikase Therapeutics’ Promising Developments and Financial Backing Justify Buy RatingNovember 15, 2024 | markets.businessinsider.com Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IKT Media Mentions By Week IKT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IKT News Sentiment▼1.671.03▲Average Medical News Sentiment IKT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IKT Articles This Week▼11▲IKT Articles Average Week Get the Latest News and Ratings for IKT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ATYR News ALMS News ARCT News EOLS News BCYC News TECX News NBTX News CGEM News PRME News PRTA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:IKT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access